Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3285184 | Clinical Gastroenterology and Hepatology | 2007 | 6 Pages |
Abstract
Background & Aims: The impact of interferon (IFN) treatment on the occurrence of complications related to hepatitis C virus (HCV)-related cirrhosis is debated because the majority of studies are retrospective. We designed a randomized controlled trial comparing the efficacy of prolonged IFN alfa-2a treatment vs nontreatment on complication-free survival in patients with compensated HCV cirrhosis. Methods: A total of 102 patients (mean age, 60.5 ± 9.5 y; male/female ratio, .82) with biopsy examination-proven HCV cirrhosis, Child-Pugh score A, who were hepatocellular carcinoma (HCC) free, and had at least 1 risk factor of complications were randomized to receive IFN or no therapy for 24 months. Results: During the follow-up evaluation, the complication rate was 24.5%: HCC occurred in 12 and decompensation unrelated to HCC occurred in 13 patients. The number of HCC patients was similar in both groups. The probability of complication-free survival was not significantly different between treated and untreated patients (98% and 72.3% vs 90% and 70.7% at 12 and 24 mo, respectively, P = .59). The median time until complication occurrence was 17.1 months in the treated group vs 13.6 months in the untreated group (P = .2). Conclusions: This randomized controlled trial showed that a 2-year course of IFN has little or no impact on complication-free survival in patients with high-risk compensated HCV cirrhosis.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Laetitia Fartoux, Françoise Degos, Christian Trépo, Odile Goria, Paul Calès, Albert Tran, Catherine Buffet, Thierry Poynard, Dominique Capron, Jean-Jacques Raabe, Dominique Roulot, Sylvie Naveau, Jean-Didier Grange, Renée E. Poupon, Raoul Poupon,